Pub. Date : 2008 Jul 4
PMID : 18482988
8 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Arsenic trioxide augments Chk2/p53-mediated apoptosis by inhibiting oncogenic Wip1 phosphatase. | Arsenic Trioxide | tumor protein p53 | Homo sapiens |
| 2 | It has been reported that arsenic trioxide (ATO), a potent cancer chemotherapeutic agent, in particular for acute promyelocytic leukemia, activates the Chk2/p53 pathway, leading to apoptosis. | Arsenic Trioxide | tumor protein p53 | Homo sapiens |
| 3 | It has been reported that arsenic trioxide (ATO), a potent cancer chemotherapeutic agent, in particular for acute promyelocytic leukemia, activates the Chk2/p53 pathway, leading to apoptosis. | Arsenic Trioxide | tumor protein p53 | Homo sapiens |
| 4 | ATO is also known to activate the p38 MAPK/p53 pathway. | Arsenic Trioxide | tumor protein p53 | Homo sapiens |
| 5 | Importantly, this ATO-induced activation of Chk2/p53 and p38 MAPK/p53 apoptotic pathways can be enhanced by siRNA-mediated suppression of Wip1 expression, further indicating that ATO inhibits Wip1 phosphatase in vivo. | Arsenic Trioxide | tumor protein p53 | Homo sapiens |
| 6 | Importantly, this ATO-induced activation of Chk2/p53 and p38 MAPK/p53 apoptotic pathways can be enhanced by siRNA-mediated suppression of Wip1 expression, further indicating that ATO inhibits Wip1 phosphatase in vivo. | Arsenic Trioxide | tumor protein p53 | Homo sapiens |
| 7 | Importantly, this ATO-induced activation of Chk2/p53 and p38 MAPK/p53 apoptotic pathways can be enhanced by siRNA-mediated suppression of Wip1 expression, further indicating that ATO inhibits Wip1 phosphatase in vivo. | Arsenic Trioxide | tumor protein p53 | Homo sapiens |
| 8 | Importantly, this ATO-induced activation of Chk2/p53 and p38 MAPK/p53 apoptotic pathways can be enhanced by siRNA-mediated suppression of Wip1 expression, further indicating that ATO inhibits Wip1 phosphatase in vivo. | Arsenic Trioxide | tumor protein p53 | Homo sapiens |